Pre-existing singleton E138A mutations in the reverse transcriptase gene do not affect the efficacy of first-line antiretroviral therapy regimens using rilpivirine in human immunodeficiency virus-infected patients.
Discussion: In a study of patients entering the SENSE trial for first-line ART in Europe, Russia, and Israel, 13.9% of patients presented with at least one polymorphic mutation in their baseline plasma (V90I, V106I, or E138A), without any impact on the virological outcomes of an etravirine-based ART program.
Genetic Diversity and Acquired Drug Resistance Mutations Detected by Deep Sequencing in Virologic Failures among Antiretroviral Treatment Experienced Human Immunodeficiency Virus-1 Patients in a Pastoralist Region of Ethiopia.
Result: CS detected an additional 7 individuals with mutations conferring drug resistance to etravirine only (E38AV; V90IV; E138A; V179T; A98AG, V179T; V179DV; and A98G), who were wild-type at OLA codons.
Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy.
PMID: 31976534
2020
The Journal of antimicrobial chemotherapy
Abstract: In comparison, the prevalence of the common NNRTI mutations V90I, K101E/P, K103N/S, E138A/G/K/Q/R/S, Y181C/I/V and G190A/E/S/Q were higher (8.9%, 7.9%, 28.6%, 12.6%, 14.2% and 8.9%, respectively).
High resistance to reverse transcriptase inhibitors among persons infected with human immunodeficiency virus type 1 subtype circulating recombinant form 02_AG in Ghana and on antiretroviral therapy.
Abstract: Non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance mutations, K103N, Y181C, V90I, F227L, and V106A were also prevalent.
Discussion: NNRTI associated mutations detected included V90I, K103N, Y181C, H221Y, K101H, G190A, V106A, F227L, and K238T.
Pharmaceutical, clinical, and resistance information on doravirine, a novel non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infection.
Introduction: Across those clinical isolates (no subtype information was provided), DOR displayed a good antiviral activity with fold changes in EC50<9 against most single mutant viruses, including A98G, E138A/G/K/Q, G190A, K101E/P, K103N/S, L100I, P236L, V106M, V108I, V197D, V90I, Y181C/V, and Y188H/C.
Natural polymorphisms in HIV-1 CRF01_AE strain and profile of acquired drug resistance mutations in a long-term combination treatment cohort in northeastern China.
Introduction: For example, V90I and V179E occurred more frequently after treatment with etravirine (ETR) and rilpivirine (RPV) in non-B HIV-1 compared to subtype B HIV-1.
Discussion: A study on a London cohort in the United Kingdom found that different baseline polymorphisms, including V90I, A98S, and K103R, were associated with virologic failure, but their effects could not be differentiated from the impacts of the different treatment regimens and HIV strains.
Genetic diversity and antiretroviral resistance-associated mutation profile of treated and naive HIV-1 infected patients from the Northwest and Southwest regions of Cameroon.
Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.
PMID: 31430369
2019
The Journal of antimicrobial chemotherapy
HIV mutation literature information.
PMID: 
2022
Clinical case reports
Browser Board
Co-occurred Entities
Filtrator
ViMRT